Clinical trials are a series of studies that help evaluate the safety and efficacy of a newly discovered drug. Although government funds around 80% of basic research to discover new drugs, it does not sponsor clinical trials at a competent level. Most of the trials are financially supported by pharmaceutical companies which arecertainly a worthwhile contribution to drug discovery, but it also influences the outcome of a clinical trial by ensuring acceptable government policies. Studies revealed that industries often practice selective reporting where unfavorable results are concealed, and positive outcomes are over-published, thereby misleading policies and future research. These downsides can be countered by utilizing funds that are totally devoid of industrial interference. It was reported that medical practitioners widely accept results from government-funded research studies and degrade the integrity of industry-funded clinical trials. Government-funded clinical trials virtually result in flawless conclusions which are extensively accepted and employed in conducting future research. Unlike industry-funded research work, government-funded trials emphasize on the need of the hour and deliver a quality result which is witnessed by the emergence of 93 Nobel Prize winners through the National Institutes of Health funded research work. A survey study revealed that 68% of respondents endorsed for doubling government funds for drug development. Utilizing standard methodologies from health economics such as cost-effective analysis and health technology assessment and public-private collaborations can be a solution for several developing and underdeveloped countries which cannot afford to sponsor drug research on its own.
Introduction
C linical trials are a series of studies t h a t h e l p e v a l u a t e t h e s a f e t y and efficacy of a newly discovered drug. The outcome of these episodes erects a scientific foundation to treat diseases. An investigational new drug application (NDA) should be filed with the food and drug administration to commence a clinical trial which comprises three sequential phases with growth in sample size at every phase. Drug developers then file a NDA to obtain marketing approval for their drug. [1] The whole process is not only time-consuming but also expensive owing to the regulatory demands and strenuous guidelines. [2] Since the late 1990s, expenditures on developing pharmaceuticals has exceeded any other component of the healthcare system. 
Government share in clinical trial funding
Although government funds around 80% of basic research to discover new drugs, it does not sponsor clinical trials at a competent level. Most of the trials are financially supported by pharmaceutical companies. [3, 4] A study revealed that 93.3% of drugs approved in the United States from This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercialShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. 1990 to 1999 were funded by pharmaceutical industries while mere 3.2% were supported by government funds.
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Consequences of industry-funded clinical trials
Sponsorship from pharmaceutical companies is certainly a worthwhile contribution to drug discovery. However, the financial power can also influence the outcome of a clinical trial by ensuring acceptable government policies. [5] They could hesitate to refrain from using power in the research activity. [6] Studies from the past revealed that industry-funded trials concludes with a positive result far more often than research funded by other sources. [7] [8] [9] Djulbegovic et al. have reported that a higher rate of success in industry-funded research is a result of "uncertainty principle" violation. These studies also hinges on a comparison of the novel drug with a placebo rather than a reputed drug which has the potential to undermine the former. [9] [10] [11] These biases not only obscure the veracity but also direct physicians to follow a flawed therapy for their patients. [12] Furthermore, variation in the publication of the clinical trial result is also reported. Several studies revealed that industries often practice selective reporting where unfavorable results are concealed, and positive outcomes are over-published, thereby misleading policies and future research. [9] von Elm et al. reported that the likelihood of publication was higher in studies funded by government sources than in industry-sponsored studies. [11, 12] Not all companies are capable of funding research. Apart from abrupt ends to clinical trials, inadequate funds also lead to several other consequences such as mergers and possession of pharmaceutical companies which results in diminished innovation prospects as companies prefer to work on low-risk follow-on drug products. Furthermore, collaboration of companies escalates the prices of medicines in view of reduction in competition. [2, 6] The aforesaid downsides can be countered by utilizing funds that are totally devoid of industrial interference. [13, 14] Achieving a positive result is not the only prerequisite for a clinical trial to be considered as successful, but the outcome should help the physicians and researchers in the treatment of diseases and future research work, respectively. This can be attained by conducting clinical trials funded by government organizations as it was reported that medical practitioners widely accept results from the government-funded research studies and degrade the integrity of industry-funded clinical trials. [4] Government-funded clinical trials virtually result in flawless conclusions which are extensively accepted and employed in conducting future research. Federal research funding has led the foundation of many medical innovations. At present, the spending of the federal government on the National Institutes of Health (NIH) research is only 1% of its budget. Treatment of challenging diseases is only possible when there is a significant increment in fund allocation from the government to conduct research on novel therapeutics. [15] Unlike industry-funded research work, government-funded trials emphasize on the need of the hour and deliver a quality result which is witnessed by the emergence of 93 Nobel Prize winners through NIH funded research work. [2, 15] A survey study revealed that 68% of respondents endorsed for doubling government funds for the drug development. [15] Moreover, regulatory agencies such as the European Medicines Agency should be funded extensively to rescue them from the capture of industries. [3] 
Conclusion
The drawbacks mentioned in the present article can be countered by utilizing standard methodologies from health economics such as cost-effective analysis and health technology assessment that demonstrates the worth of novel medicine in terms of units of currency per health benefit achieved. [16] Public-private collaborations is a solution for several developing and underdeveloped countries which cannot afford to sponsor drug research on its own, thereby threatening the sustainability of research grants. This type of collaborations has more innovative potential than the individual partners and spread the risks among them without reducing the probability of developing a new medicine.
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